Botulinum toxin type A in the treatment of sialorrhea in patients with Parkinson’s disease

Authors

  • Alma Yolanda Alvarado-Gutiérrez
  • Jorge Hernández-Franco
  • Israel Sánchez-Villavicencio

DOI:

https://doi.org/10.31157/an.v20i3.89

Keywords:

drooling, Parkinson’s disease, botulinum toxin.

Abstract

Drooling is defined as excess saliva in the mouth that exceeds the margin of the lips. The injection of botulinum toxin type A appears to be the safest as it offers a range of effectiveness up to 3 months. Objectives: To study whether low (75 units) of abobotoxina type in the parotid gland of patients with Parkinson’s disease and drooling, dose is effective without the presence of adverse effects. Methods: cross-sectional study in patients with drooling scale clinical scale for Parkinson disease (SCS-PD), severity and frequency of salivation (DSFS), at the time of study entry and at weeks 1, 2, 4 , 8, 12, 16. Results: 6 patients were included in the study, with a mean age of 67.3 years, 11.8 years on average for developing Parkinson’s four years of suffering drooling. Analysis of decreasing an overall score for SCS-PD from baseline to week 12, presents statistical significance (p = 0.0030) thus corroborating the beneficial effect of the toxin for at least 3 months. Conclusions: a dose of 75 units abobotoxina type A appears to be suitable for symptom control without creating undesirable side effects start from the first week of the application keeping up to 3 months after starting treatment.

Published

2015-09-01

How to Cite

Alvarado-Gutiérrez, A. Y., Hernández-Franco, J., & Sánchez-Villavicencio, I. (2015). Botulinum toxin type A in the treatment of sialorrhea in patients with Parkinson’s disease. Archivos De Neurociencias, 20(3), 174–181. https://doi.org/10.31157/an.v20i3.89

Issue

Section

Original Articles